These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 6694918)

  • 1. Estramustine-induced mitotic arrest in two human prostatic carcinoma cell lines DU 145 and PC-3.
    Hartley-Asp B
    Prostate; 1984; 5(1):93-100. PubMed ID: 6694918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytotoxic properties of estramustine unrelated to alkylating and steroid constituents.
    Tew KD; Hartley-Asp B
    Urology; 1984 Jun; 23(6 Suppl):28-33. PubMed ID: 6730140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth and cell survival following treatment with estramustine nor-nitrogen mustard, estradiol and testosterone of a human prostatic cancer cell line (DU 145).
    Hartley-Asp B; Gunnarsson PO
    J Urol; 1982 Apr; 127(4):818-22. PubMed ID: 7069864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormone-independent, non-alkylating mechanism of cytotoxicity for estramustine.
    Tew KD; Stearns ME
    Urol Res; 1987; 15(3):155-60. PubMed ID: 3307087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship of glutathione depletion and inhibition of glutathione-S-transferase activity to the antimitotic properties of estramustine.
    Tew KD; Woodworth A; Stearns ME
    Cancer Treat Rep; 1986 Jun; 70(6):715-20. PubMed ID: 3731136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence for a non-estrogenic cytostatic effect of estramustine on human prostatic carcinoma cells in vivo.
    Eklöv S; Nilsson S; Larson A; Björk P; Hartley-Asp B
    Prostate; 1992; 20(1):43-50. PubMed ID: 1736276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nuclear protein matrix as a target for estramustine-induced cell death.
    Hartley-Asp B; Kruse E
    Prostate; 1986; 9(4):387-95. PubMed ID: 3786258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimicrotubule effects of estramustine, an antiprostatic tumor drug.
    Stearns ME; Tew KD
    Cancer Res; 1985 Aug; 45(8):3891-7. PubMed ID: 4016756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunofluorescent studies of the anti-microtubule effects of the anti-cancer drug estramustine.
    Wang M; Tew KD; Stearns ME
    Anticancer Res; 1987; 7(6):1165-71. PubMed ID: 3327449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of advanced carcinoma of the prostate with estramustine phosphate.
    Nagel R; Köllin CP
    Br J Urol; 1977 Feb; 49(1):73-9. PubMed ID: 837052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estramustine-binding protein (EMBP) content in four different cell lines and its correlation to estramustine induced metaphase arrest.
    Eklöv S; Mahdy E; Wester K; Björk P; Malmström PU; Busch C; Nilsson S
    Anticancer Res; 1996; 16(4A):1819-22. PubMed ID: 8712706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma concentrations of estramustine phosphate and its major metabolites in patients with prostatic carcinoma treated with different doses of estramustine phosphate (Estracyt).
    Gunnarsson PO; Forshell GP; Fritjofsson A; Norlén BJ
    Scand J Urol Nephrol; 1981; 15(3):201-5. PubMed ID: 7323739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dansylated estramustine, a fluorescent probe for studies of estramustine uptake and identification of intracellular targets.
    Stearns ME; Jenkins DP; Tew KD
    Proc Natl Acad Sci U S A; 1985 Dec; 82(24):8483-7. PubMed ID: 3866236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of estramustine and prednimustine versus prednimustine alone in advanced metastatic prostatic cancer patients who have received prior irradiation.
    Murphy GP; Gibbons RP; Johnson DE; Prout GR; Schmidt JD; Soloway MS; Loening SA; Chu TM; Gaeta JF; Saroff J; Wajsman Z; Slack N; Scott WW
    Trans Am Assoc Genitourin Surg; 1978; 70():69-71. PubMed ID: 753026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of estramustine and its constituents on human malignant glioma cells.
    von Schoultz E; Lundgren E; Henriksson R
    Anticancer Res; 1990; 10(3):693-6. PubMed ID: 2369085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth inhibiting effect of estramustine on two prostatic carcinoma cell lines, LNCaP and LNCaP-r.
    Hansenson M; Lundh B; Hartley-Asp B; Pousette A
    Urol Res; 1988; 16(5):357-61. PubMed ID: 3201650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiinvasive activity of estramustine on malignant MO4 mouse cells and on DU-145 human prostate carcinoma cells in vitro.
    Mareel MM; Storme GA; Dragonetti CH; De Bruyne GK; Hartley-Asp B; Segers JL; Rabaey ML
    Cancer Res; 1988 Apr; 48(7):1842-9. PubMed ID: 3349462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estramustine phosphate: a specific chemotherapeutic agent?
    Von Hoff DD; Rozencweig M; Slavik M; Muggia FM
    J Urol; 1977 Apr; 117(4):464-6. PubMed ID: 850319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized double blind crossover trial of diethylstilbestrol (DES) and estramustine phosphate (Emcyt) for stage D prostatic carcinoma.
    Benson RC; Gill GM; Cummings KB
    Semin Oncol; 1983 Sep; 10(3 Suppl 3):43-5. PubMed ID: 6364366
    [No Abstract]   [Full Text] [Related]  

  • 20. Induction of aneuploidy by the antineoplastic drug estramustine in human lymphocytes.
    Migliore L; Cocchi L; Scarpato R; Sbrana I
    Mutat Res; 1998 Jan; 412(1):33-40. PubMed ID: 9508362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.